JP2019510739A - Ｇｆｒａｌ受容体療法 - Google Patents

Ｇｆｒａｌ受容体療法 Download PDF

Info

Publication number
JP2019510739A
JP2019510739A JP2018540415A JP2018540415A JP2019510739A JP 2019510739 A JP2019510739 A JP 2019510739A JP 2018540415 A JP2018540415 A JP 2018540415A JP 2018540415 A JP2018540415 A JP 2018540415A JP 2019510739 A JP2019510739 A JP 2019510739A
Authority
JP
Japan
Prior art keywords
compound
gfral
mammal
gdf15
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510739A5 (enExample
Inventor
シンラー・ウー
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2019510739A publication Critical patent/JP2019510739A/ja
Publication of JP2019510739A5 publication Critical patent/JP2019510739A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018540415A 2016-02-29 2016-02-29 Ｇｆｒａｌ受容体療法 Pending JP2019510739A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/074809 WO2017147742A1 (en) 2016-02-29 2016-02-29 Gfral receptor therapies

Publications (2)

Publication Number Publication Date
JP2019510739A true JP2019510739A (ja) 2019-04-18
JP2019510739A5 JP2019510739A5 (enExample) 2019-05-30

Family

ID=59742416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540415A Pending JP2019510739A (ja) 2016-02-29 2016-02-29 Ｇｆｒａｌ受容体療法

Country Status (4)

Country Link
EP (1) EP3423094A4 (enExample)
JP (1) JP2019510739A (enExample)
CN (1) CN108697795A (enExample)
WO (1) WO2017147742A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021246773A1 (ko) * 2020-06-04 2021-12-09 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
JP2024511853A (ja) * 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
AU2017228489A1 (en) * 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
WO2018071493A1 (en) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
ES3061099T3 (en) 2019-10-04 2026-03-31 Amgen Inc Use of gdf15 for treating cardiometabolic syndrome and other conditions
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN117693525A (zh) * 2021-06-30 2024-03-12 上海津曼特生物科技有限公司 抗gfral抗体及其应用
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014511863A (ja) * 2011-04-08 2014-05-19 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
US9175076B2 (en) * 2012-12-21 2015-11-03 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076569A2 (en) * 2002-03-05 2003-09-18 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN102321173B (zh) * 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
WO2017121865A1 (en) * 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014511863A (ja) * 2011-04-08 2014-05-19 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
US9175076B2 (en) * 2012-12-21 2015-11-03 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF NEUROCHEMISTRY, vol. 95, JPN6019026575, 2005, pages 361 - 376, ISSN: 0004176784 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 34, JPN6019026577, 1991, pages 23060 - 23067, ISSN: 0004176785 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021246773A1 (ko) * 2020-06-04 2021-12-09 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
US12398211B2 (en) 2020-06-04 2025-08-26 Daegu Gyeongbuk Institute Of Science And Technology GFRAL-antagonistic antibody and use thereof
JP2024511853A (ja) * 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤

Also Published As

Publication number Publication date
EP3423094A4 (en) 2019-11-06
CN108697795A (zh) 2018-10-23
EP3423094A1 (en) 2019-01-09
WO2017147742A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
WO2017147742A1 (en) Gfral receptor therapies
TWI832808B (zh) 中和抗tl1a之單株抗體
RU2758113C2 (ru) Антитела к muc16 и их применение
JP5165672B2 (ja) Ｔｓｈｒに対するアゴニスト抗体
JP2022179611A (ja) 抗ｃｔｌａ４抗体及びその用途
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
RU2702553C2 (ru) Новое антитело против tie-2 человека
JP7825633B2 (ja) ガレクチン－３に対する抗体及びその使用方法
TWI832013B (zh) 一種抗pd-l1抗原結合蛋白及其應用
CN105658237B (zh) 抗Ly6E抗体及使用方法
WO2013147212A1 (ja) 新規抗Ｓｉｇｌｅｃ－１５抗体
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
US11542329B2 (en) Antibodies targeting Glycoprotein VI
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
CN110724193A (zh) 人单克隆抗il-32抗体、多核苷酸、载体、宿主细胞、制备方法、组合物及应用
JP2021527081A (ja) ストレス関連障害および癌を治療するための材料および方法
JP2021535078A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
WO2022242757A1 (zh) 抗pd-1抗体的应用
WO2015176104A1 (en) Bak binding proteins
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
CN120584130A (zh) 用纳米抗体靶向gpr158(mglyr)用于治疗益处
HK1234078A1 (en) Novel anti-human tie2 antibody

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107